The FDA has approved a labeling update for Leqvio (inclisiran) allowing for first-line use in the treatment of hypercholesterolemia.

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

The US Food and Drug Administration approved the revised label for inclisiran, a small interfering RNA that reduces the ...

In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $420.41, a high estimate of $570.00, and a low estimate of $333.00.

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

The money will support dozens of different approaches for improving women’s health, from new medicines to prevent maternal ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

The EMA's CHMP has backed approval of Novartis drug Leqvio (inclisiran) to treat adults with hypercholesterolaemia or mixed dyslipidaemia ...

Q2 2025 Earnings Call Transcript July 31, 2025 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...